

Integrated Impact Assessment Report for Service Specifications			
Service Specification Reference Number	URN 1706		
Service Specification Title	Auditory brainstem implant with congenital abnormalities of the auditory nerves or cochleae Proposal <u>for routine commission</u> (source A3.1)		
Lead Commissioner	Nicola Symes	Clinical Lead	Shakeel Saeed
Finance Lead	Peter Davis	Analytical Lead	Jacqueline Low

Integrated Impact Assessment - Index				
Section A – Activity Section B - Service Section C – Finance				
A1 Current Patient Population & Demography / Growth	B1 Service Organisation	C1 Tariff		
A2 Future Patient Population & Demography	B2 Geography & Access	C2 Average Cost per Patient		
A3 Activity	B3 Implementation	C3 Overall Cost Impact of this service specification to NHS England		
A4 Patient Pathway	B4 Collaborative Commissioning	C4 Overall cost impact of this service specification to the NHS as a whole		
A5 Service Setting		C5 Funding		
A6 Coding		C6 Financial Risks Associated with Implementing this service specification		
A7 Monitoring		C7 Value for Money		
		C8 Cost Profile		

About this Impact Assessment: instructions for completion and explanatory notes

- Each section is divided into themes.
- Each theme sets out a number of questions.
- All questions are answered by selecting a drop down option or including free text.
- Free text boxes are provided to enable succinct relevant commentary to be added which explains the rationale for response or assumption. Please limit responses to 3 sentences of explanatory text.
- Data in this document is either drawn from one of the relevant service specification documents or a source for the information is provided.
- Where assumptions are included where data is not available, this is specified.

Section A - Activity Impact			
A1 Current Patient Population & Demography / Growth			
A1.1 Prevalence of the disease/condition.	functional hearing as a r nerve or the cochleae, the conventional well-fitted I	e years or under, with profound deafness, who have no result of congenital abnormalities affecting the auditory hus rendering them unable to gain adequate benefit from hearing aids or cochlear implants cation Proposition section 3.1	
A1.2 Number of patients currently eligible for the service according to the proposed service specification commissioning criteria.	Source: Clinical Consensus based on clinical indications Please specify Click here to enter text.		
A1.3 Age group for which the service is proposed according to the service specification commissioning criteria.	Children Please specify Children aged 5 and under		
A1.4 Age distribution of the patient population eligible according to the proposed service specification commissioning criteria	Children aged 5 and under Source: Service Specification Proposition section 3.1 Please specify Click here to enter text.		
A1.5 How is the population currently distributed geographically? Evenly If unevenly, estimate regional distribution by %:		gional distribution by %:	
	North Midlands & East	enter % enter %	

	London	enter %	
	South	enter %	
	Source: Service sp	ecification proposition section 6	
	Please specify Click here to enter text.		
A2 Future Patient Population & Demography			
A2.1 Projected changes in the disease/condition epidemiology, such as incidence or prevalence (prior to applying the new service specification) in 2, 5, and 10	Constant If other Click here to	co optor toxt	
years?	If other, Click here to enter text. Source: Service specification proposition section 3.1		
	Source. Service specification proposition section 3.1		
A2.2 Are there likely to be changes in demography of the	<u>No</u>		
patient population and would this impact on	Please specify		
activity/outcomes?	Click here to enter text.		
	Source: Service specification proposition section 6/other		
A2.3 Expected net increase or decrease in the number of	YR2 +/-	0	
patients who will be eligible for the service, according to the		0	
proposed service specification commissioning criteria, per year in years 2-5 and 10?		0	
year in years 2 5 and 10:		0	
		0	
	Source: Service sp	ecification proposition section 3.1	
Are these numbers in line with ONS growth assumptions			

for the age specific population? If not please justify the growth assumptions made.	There is not expected to be annual growth in the number of children meeting the criteria for this service.
A3 Activity	
A3.1 What is the purpose of new service specification?	Provide service specification for a new service approved to be commissioned by NHS England for the first time in accordance with PSSAG / other recommendation *PSSAG (Prescribed Specialised Services Advisory Group) Please specify
	Routine clinical commissioning policy approved December 2016 https://www.england.nhs.uk/wp-content/uploads/2016/12/clin-comm-pol-16062P.pdf
A3.2 What is the annual activity associated with the existing pathway for the eligible population?	O Source: Clinical Consensus Please specify Click here to enter text.
A3.3 What is the estimated annual activity associated with the proposed service specification proposition pathway for the eligible population?	15 assessments; 9 surgical procedures Source: Clinical Consensus Click here to enter text.
A4 Patient Pathway	
A4.1 Patient pathway Describe the current patient pathway and service.	Children (aged 5 or under) would normally be referred to this highly specialised service by a local auditory implant centre, where, following initial assessment, they

	are considered unlikely to gain adequate benefit from conventional well-fitted hearing aids or cochlear implants
	Source: Service Specification section 2.1 / Clinical Consensus
A4.2. What are the current service access and stopping criteria?	Following referral, all children will undergo further comprehensive assessment by a specialist multi-disciplinary team to assess suitability for auditory brainstem implantation. For children who meet the suitability criteria, the service will provide appropriate surgical auditory brainstem implantation. If, following a multi-disciplinary team assessment, it is determined that a child is not suitable for an auditory brainstem implant, the service will ensure that parents/carers and the referrer are provided with the information and advice prior to discharge from the service Source: Service Specification / Clinical Consensus
A4.3 What percentage of the total eligible population are:	If not known, please specify Not known – new service
a) Referred b) Meet any existing criteria for care c) Considered to meet any existing exclusion criteria	a) enter % b) enter % c) enter % Source: Click here to enter text.
A4.4 What percentage of the total eligible population is	If not known, please specify Not known – new service
expected to:	a) enter %
a) Be referred to the proposed service b) Be eligible for care according to the proposed	b) enter %
criteria for the service	c) enter %
c) Take up care according to the proposed criteria for	
the service	d)
d) Continue care according to the proposed criteria for the service?	Source: required
A4.5 Specify the nature and duration of the proposed new	Life long

service or intervention.	For time limited services, specify frequency and/or duration.		
	Click here to enter text.		
	Source: required	•	
A5 Service Setting			
A5.1 How is this service delivered to the patient?	Select all that apply:		
	Emergency/Urgent care atte	endance [
	Acute Trust: inpatient	Σ	
	Acute Trust: day patient		
	Acute Trust: outpatient	Σ	
	Mental Health provider: inpa	atient	
	Mental Health provider: outpatient □		
	Community setting		
	Homecare		
	Other		
	Please specify:		
	Click here to enter text.		
A5.2 What is the current number of contracted providers for	NORTH	0	
the eligible population by region?	MIDLANDS & EAST	0	
	LONDON	0	
	SOUTH	0	

A5.3 Does the proposition require a change of delivery setting or capacity requirements?	Please specify: The new service will require selected centres to be able to demonstrate that they have the required capacity to fulfil the requirements of this service. However, patient numbers are expected to be low volume, so impact on total workload within those selected centres will be limited. Source Clinical Consensus		
A6 Coding			
A6.1 Specify the datasets used to record the new patient	Select all that apply:		
pathway activity.	Aggregate Contract Monitoring *	\boxtimes	
*expected to be populated for all commissioned activity	Patient level contract monitoring		
	Patient level drugs dataset		
	Patient level devices dataset		
	Devices supply chain reconciliation dataset		
	Secondary Usage Service (SUS+)		
	Mental Health Services DataSet (MHSDS)		
	National Return**		
	Clinical Database**		
	Other**	\boxtimes	
	**If National Return, Clinical database or other via Highly Specialised Services data returns	selecte	d, please specify: Monitoring

A6.2 Specify how the activity related to the new patient	Select all that apply:		
pathway will be identified.	OPCS v4.8	\boxtimes	
	ICD10		
	Service function code		
	Main Speciality code		
	HRG		
	SNOMED		
	Clinical coding / terming methodology used by clinical profession		
A6.3 Identification Rules for Drugs:	Not applicable		
How are any drug costs captured?	If already specified in the current NHS England Drug / Devices List, please specify drug name and indication for all that apply:		
	Click here to enter text.		
	If drug(s) NOT already been specified in the cugive details of action required and confirm that pharmacy lead:	O O 1	
40	Click here to enter text.		
A6.4 Identification Rules for Devices:	Already covered by an existing category of	HCTED and commissioned via the	
How are device costs captured?	Zero Cost Model		
	If device(s) covered by an existing category of I Category (as per the National Tariff Payment S		
	Bone Anchored Hearing Aids		
	If device(s) not excluded from Tariff nor covered within existing National or Local		
	prices please specify details of action required discussed with the HCTED team.	and confirm that this has been	

	Click here to enter text.
A6.5 Identification Rules for Activity:	Already correctly captured by an existing specialised service line (NCBPS
How are activity costs captured?	code within the PSS Tool
	If activity costs are already captured please specify the specialised service code and description (e.g. NCBPS01C Chemotherapy).
	NCBPS23M Paediatric Neurosurgery: A091 Implantation of Neurostimulator in to the Brain
	If activity costs are already captured please specify whether this service needs a separate code. No
	If the activity is captured but the service line needs amendment please specify whether the proposed amendments have been documented and agreed with the Identification Rules team.
	Click here to enter text.
	If the activity is not captured please specify whether the proposed identification rules have been documented and agreed with the Identification Rules team.
A7 Monitoring	
A7.1 Contracts	Yes - other
Specify any new or revised data flow or data collection	Please specify
requirements, needed for inclusion in the NHS Standard Contract Information Schedule.	Monitoring via Highly Specialised Services data returns
Please identify any excluded drugs or devices relevant to	
the service and their current status with regard to NHS England specialised services commissioning.	
A7.2 Business intelligence	<u>No</u>
Is there potential for duplicate reporting?	If yes, please specify mitigation:

	Click here to enter text.
A7.3 Contract monitoring	<u>Yes</u>
Is this part of routine contract monitoring?	If no, please specify contract monitoring requirement:
	Click here to enter text.
A7.4 Dashboard reporting	<u>No</u>
Specify whether a dashboard exists for the proposed service?	If yes, specify how routine performance monitoring data will be used for dashboard reporting.
	Click here to enter text.
	If no, will one be developed?
	No, patient numbers too small, but will be subject to clinical audit and outcome monitoring.
A7.5 NICE reporting	<u>No</u>
Are there any directly applicable NICE or equivalent quality	If yes, specify how performance monitoring data will be used for this purpose.
standards which need to be monitored in association with the new service specification?	Click here to enter text.
Se	ection B - Service Impact
B1 Service Organisation	
B1.1 Describe how the service is currently organised? (i.e.	Not applicable – new service
tertiary centres, networked provision etc.)	Source: required
B1.2 Will the specification change the way the	Yes
commissioned service is organised?	Please specify:

	New service to be commissioned		
	Source: required		
	Godice. regained		
B1.3 Will the specification require a new approach to the			
organisation of care?	Please specify:	X	
	Following provider selection, any designated centres will need to work collaboratively as part of a national network.		
B2 Geography & Access			
B2.1 Where do current referrals come from?	Select all that apply:		
	GP		
	Secondary care		
	Tertiary care		
	Other		
	Please specify:	_ 	
	Specialist Paediatric Audiolog	y Implant Centres	
B2.2 What impact will the new service specification have	No impact		
on the sources of referral?	Please specify:		
	Children will already be known to Specialist Paediatric Audiology Implant Centres		
B2.3 Is the new service specification likely to improve	Increase		
equity of access?	Please specify:		
	Click here to enter text.		
Source: Equalities Impact Assessment		sessment	

B2.4 Is the new service specification likely to improve equality of access and/or outcomes?	Increase Please specify: Click here to enter text. Source: Equalities Impact Assessment
B3 Implementation	
B3.1 Will commissioning or provider action be required before implementation of the proposition can occur?	Provider selection action Please specify: Click here to enter text.
B3.2 Time to implementation: Is a lead-in time required prior to implementation?	Yes - go to B3.3 If yes, specify the likely time to implementation: Subject to provider selection timetable
B3.3 Time to implementation: If lead-in time is required prior to implementation, will an interim plan for implementation be required?	Yes If yes, outline the plan: Interim arrangements currently in place following approval of clinical commissioning policy in December 2016. Provider Selection estimated to take 6 months from approval.
B3.4 Is a change in provider physical infrastructure required?	No Please specify: Click here to enter text.
B3.5 ls a change in provider staffing required?	No Please specify:

	Click here to	enter text.			
B3.6 Are there new clinical dependency and/or adjacency requirements that would need to be in place?	No Please specifical Click here to	•	A CO		
B3.7 Are there changes in the support services that need to be in place?	No Please specify: Click here to enter text.				
B3.8 Is there a change in provider and/or inter-provider governance required? (e.g. ODN arrangements / prime contractor)	No Please specifical Click here to				
B3.9 Is there likely to be either an increase or decrease in the number of commissioned providers? If yes, specify the	Increase Please complete the table:				
current and estimated number of providers required in each region	Region	Current no. of providers	Future State expected range	Provisional or confirmed	
$\mathcal{C}(\mathcal{C})$	North			select	
	Midlands & East			select	
	London			select	
	South			select	
	Total	0	2 - 3	<u>P</u>	
	Please specif Subject to pro	y: ovider selection			

B3.10 Specify how revised provision will be secured by	Select all that apply:	
NHS England as the responsible commissioner.	Publication and notification of new service specification	
	Market intervention required	
	Competitive selection process to secure increase or decrease provider configuration	
	Price-based selection process to maximise cost effectiveness	
	Any qualified provider	
	National Commercial Agreements e.g. drugs, devices	
	Procurement	
	Other	
	Please specify:	
	Click here to enter text.	
B4 Place-based Commissioning		
B4.1 Is this service currently subject to, or planned for,	No	
place-based commissioning arrangements? (e.g. future	Please specify:	
CCG lead, devolved commissioning arrangements, STPs)	Click here to enter text.	
Se	ection C - Finance Impact	
C1 Tariff/Pricing		

C1.1 How is the service contracted and/or charged?	Select all that apply:		
Only specify for the relevant section of the patient pathway		Not separately charged – part of local or national tariffs	
	Drugs	Excluded from tariff – pass through	
		Excluded from tariff - other	
		Not separately charged – part of local or national tariffs	
	Davissa	Excluded from tariff (excluding ZCM) – pass through	
	Devices	Excluded from tariff (excluding ZCM) – other	
		Via Zero Cost Model	
	Activity	Paid entirely by National Tariffs	\boxtimes
		Paid entirely by Local Tariffs	
		Partially paid by National Tariffs	
		Partially paid by Local Tariffs	
		Part/fully paid under a Block arrangement	
		Part/fully paid under Pass-Through arrangements	
		Part/fully paid under Other arrangements	
C1.2 Drug Costs	Not applica	able	
Where not included in national or local tariffs, list each drug or combination, dosage, quantity, list price including VAT if applicable and any other key information e.g. Chemotherapy Regime.			
NB discounted prices or local prices must not be included as these are subject to commercial confidentiality and must not be disclosed.			

C1.3 Device Costs

Where not included in national or local tariff, list each element of the excluded device, quantity, **list or expected** price including VAT if applicable and any other key information.

NB: Discounted prices or local prices must not be included as these are subject to commercial confidentiality and must not be disclosed.

Included in tariff

C1.4 Activity Costs covered by National Tariff

List all the HRG codes, HRG descriptions, national tariffs (excluding MFF), volume and other key costs (e.g. specialist top up %)

It is anticipated that up to 15 children may be referred annually for assessment, with up to 9 children continuing to surgery and follow-up.

HRG code	HRG name	Combined day case / ordinary elective spell tariff (£)
AA50D	Very Complex Intracranial Procedures, 18 years and under, with CC Score 12+	40,550

Treatment function code	Treatment function description	WF01B First Attendance - Single Professional	WF01A Follow Up Attendance - Single Professional
215	Paediatric Ear Nose and Throat	120	61
Treatment function code	Treatment function name	WF01B First Attendance - Single Professional	WF01A Follow Up Attendance - Single Professional
218	Paediatric Neurosurgery	238	141

C1.5 Activity Costs covered by Local Tariff	Not applicable
List all the HRGs (if applicable), HRG or local description, estimated average tariff, volume and any other key costs. Also indicate whether the Local Tariff(s) is/are newly proposed or established and if newly proposed how is has been derived, validated and tested.	
C1.6 Other Activity Costs not covered by National or Local Tariff	Not applicable
Include descriptions and estimates of all key costs.	
C1.7 Are there any prior approval mechanisms required either during implementation or permanently?	No Please specify: Click here to enter text.
C2 Average Cost per Patient	
C2.1 What is the estimated cost per patient to NHS England, in years 1-5, including follow-up where required?	As modelled clinical commissioning policy approved during December 2016 CPAG prioritisation
(,()	YR1 61,193
	YR2 2,000
Are there any changes expected in year 6.10 which would	YR3 2,000
Are there any changes expected in year 6-10 which would impact the model?	YR4 1,000
	YR5 1,000
	If yes, please specify: Not applicable

C3 Overall Cost Impact of this Service specification to NHS England		
C3.1 Specify the budget impact of the proposal on NHS England in relation to the relevant pathway.	Cost neutral Please specify: Service specification proposition is in line with agreed published clinical commissioning policy approved during December 2016 CPAG prioritisation https://www.england.nhs.uk/wp-content/uploads/2016/12/clin-comm-pol-16062P.pdf	
C3.2 If the budget impact on NHS England cannot be identified set out the reasons why this cannot be measured.	Not applicable	
C3.3 If the activity is subject to a change of commissioning responsibility, from CCG to NHS England, has a methodology for the transfer of funds been identified, and calculated?	Not applicable	
C4 Overall cost impact of this service specification to th	e NHS as a whole	
C4.1 Specify the budget impact of the proposal on other parts of the NHS.	Budget impact for CCGs: No impact on CCGs Budget impact for providers: No impact on providers Please specify: Click here to enter text.	

C4.2 Taking into account responses to C3.1 and C4.1, specify the budget impact to the NHS as a whole.	Cost neutral Please specify: Click here to enter text.
C4.3 Where the budget impact is unknown set out the reasons why this cannot be measured	Not applicable
C4.4 Are there likely to be any costs or savings for non-NHS commissioners and/or public sector funders?	Unknown Please specify: Click here to enter text.
C5 Funding	
C5.1 Where a cost pressure is indicated, state known source of funds for investment, where identified, e.g. decommissioning less clinically or cost-effective services.	Not applicable
C6 Financial Risks Associated with Implementing this S	Service specification
C6.1 What are the material financial risks to implementing this service specification?	There are no significant financial risks associated with this specification, due to the financial and activity modelling completed and very low patient volumes.
C6.2 How can these risks be mitigated?	Not applicable
C6.3 What scenarios (differential assumptions) have been explicitly tested to generate best case, worst case and most likely total cost scenarios?	There will be a fixed local tariff associated with this service and small patient cohort, therefore the most likely total costs scenario has been calculated.

C6.4 What scenario has been approved and why?	Most likely scenario has been approved due to the small patient coho treatment.	ort suitable for
C7 Value for Money		
C7.1 What published evidence is available that the service is cost effective as evidenced in the evidence review?	There is no published evidence of cost-effectiveness Please specify: Click here to enter text.	
C7.2 Has other data been identified through the service	Select all that apply:	
specification development relevant to the assessment of value for money?	Available pricing data suggests the service specification is equivalent cost compared to current/comparator service specification	\boxtimes
	Available pricing data suggests the service is lower cost compared to current/comparator treatment	
	Available clinical practice data suggests the new service specification has the potential to improve value for money	
	Other data has been identified	
	No data has been identified	
	The data supports a high level of certainty about the impact on value	
	The data does not support a high level of certainty about the impact on value	
	Please specify:	
	Click here to enter text.	

C8 Non-Recurrent Costs		
C8.1 Are there non-recurrent revenue costs associated with this service specification?	If yes, please specify and indicate whether these would be incurred or passed through to NHS England: Click here to enter text. If the costs are to be passed through to NHS England please indicate whether this has been taken into account in the budgetary impact. Choose an item.	
C8.2 Are there any non-recurrent provider capital costs associated with the service specification?	No If yes, please specify and indicate with there is a separate source of funding identified (commissioners cannot reimburse capital costs). Click here to enter text.	